Richard Piekarz

7.6k total citations · 1 hit paper
137 papers, 5.3k citations indexed

About

Richard Piekarz is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Richard Piekarz has authored 137 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Molecular Biology, 58 papers in Oncology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Richard Piekarz's work include Histone Deacetylase Inhibitors Research (70 papers), Protein Degradation and Inhibitors (25 papers) and Peptidase Inhibition and Analysis (22 papers). Richard Piekarz is often cited by papers focused on Histone Deacetylase Inhibitors Research (70 papers), Protein Degradation and Inhibitors (25 papers) and Peptidase Inhibition and Analysis (22 papers). Richard Piekarz collaborates with scholars based in United States, Australia and Canada. Richard Piekarz's co-authors include Susan E. Bates, Robert W. Robey, William D. Figg, Robin Frye, Seth M. Steinberg, Maria L. Turner, James R. Wright, Antonio Tito Fojo, Erin R. Gardner and Tito Fojo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Richard Piekarz

126 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

2009 561 citations Richard Piekarz, Robin Frye et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Richard Piekarz

Since Specialization

Citations

This map shows the geographic impact of Richard Piekarz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Piekarz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Piekarz more than expected).

Fields of papers citing papers by Richard Piekarz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Piekarz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Piekarz. The network helps show where Richard Piekarz may publish in the future.

Co-authorship network of co-authors of Richard Piekarz

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Piekarz. A scholar is included among the top collaborators of Richard Piekarz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Piekarz. Richard Piekarz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome 2025 ·Cancer Chemotherapy and Pharmacology ·(unknown), Danielle Shafer, Dale Schaar, Dipankar Bandyopadhyay, (unknown), John Wright, Richard Piekarz, Michelle A. Rudek, R. Donald Harvey, Steven Grant	5
2	A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183). 2024 ·Journal of Clinical Oncology ·Maha Hussain, Masha Kocherginsky, Parminder Singh, (unknown), Zin Myint, Di Jiang, Elizabeth Wulff‐Burchfield, (unknown), Elad Sharon, Richard Piekarz, Joshua J. Meeks, David James VanderWeele	2
3	Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399 2023 ·The Oncologist ·Ryan D. Gentzler, Liza C. Villaruz, John C. Rhee, Bethany J. Horton, (unknown), Michael R. Hanley, Kyeongmin Kim, Michelle A. Rudek, Mitch A. Phelps, Michael A. Carducci, Richard Piekarz, (unknown), Timothy N. J. Bullock, Charles M. Rudin	10
4	Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia 2021 ·Leukemia Research ·Hetty E. Carraway, Yazeed Sawalha, Ivana Gojo, Min-Jung Lee, Sunmin Lee, Yusuke Tomita, Akira Yuno, (unknown), B. Douglas Smith, Keith W. Pratz, Mark J. Levis, Steven D. Gore, Nilanjan Ghosh, Amy E. DeZern, Amanda L. Blackford, Maria R. Baer, Lia Gore, Richard Piekarz, Jane B. Trepel, Judith E. Karp	10
5	A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies 2021 ·Cancer Chemotherapy and Pharmacology ·Katharine A. Collier, (unknown), Herbert B. Newton, Erinn M. Hade, Douglas W. Sborov, Robert Cavaliere, Ming Poi, Mitch A. Phelps, (unknown), Christopher C. Coss, (unknown), (unknown), Paul Monk, Charles L. Shapiro, Richard Piekarz, Craig C. Hofmeister, D. Bradley Welling, Amir Mortazavi	20
6	E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group 2021 ·Journal of Clinical Oncology ·Roisín M. Connolly, Fengmin Zhao, Kathy D. Miller, Min-Jung Lee, Richard Piekarz, Karen L. Smith, Ursa Brown‐Glaberman, (unknown), Bryan A. Faller, Adedayo A. Onitilo, Mark E. Burkard, G. Thomas Budd, Ellis Levine, Melanie Royce, Peter A. Kaufman, Alexandra Thomas, Jane B. Trepel, Antonio C. Wolff, Joseph A. Sparano	76
7	A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia 2019 ·Blood ·Kamal Menghrajani, Sheng F. Cai, Sean M. Devlin, Scott A. Armstrong, Richard Piekarz, Michelle A. Rudek, Martin S. Tallman, Eytan M. Stein	12
8	Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks 2018 ·Molecular Cancer Therapeutics ·Aashish Soni, Fanghua Li, You Wang, Martha Grabos, (unknown), (unknown), (unknown), Mansoor M. Ahmed, C. Norman Coleman, Beverly A. Teicher, Richard Piekarz, Dian Wang, George Iliakis	17
9	Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870) 2017 ·Clinical Cancer Research ·Роберто Пили, David I. Quinn, Hans J. Hammers, Paul Monk, Saby George, Tanya B. Dorff, Thomas Olencki, Li Shen, Ashley Orillion, Dominick Lamonica, (unknown), Zsolt Szabó, Alan D. Hutson, Adrienne Groman, Susan M. Perkins, Richard Piekarz, Michael A. Carducci	76
10	Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies 2017 ·Clinical Cancer Research ·(unknown), Mathangi Gopalakrishnan, Jogarao Gobburu, Jiuping Ji, Jacqueline M. Greer, Richard Piekarz, Judith E. Karp, Keith W. Pratz, Michelle A. Rudek	4
11	E2112: Randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. 2015 ·Journal of Clinical Oncology ·Roisín M. Connolly, Fengmin Zhao, Kathy Ann Miller, Amyé Tevaarwerk, Lynne I. Wagner, Min-Jung Lee, (unknown), Robert J. Gray, Richard Piekarz, Jo Anne Zujewski, Joseph A. Sparano	9
12	A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study 2014 ·Clinical Cancer Research ·Anish Thomas, Arun Rajan, Éva Szabó, Yusuke Tomita, Corey A. Carter, Barbara Scepura, Ariel López-Chávez, Min-Jung Lee, Christophe E. Redon, (unknown), Cody J. Peer, Yuanbin Chen, Richard Piekarz, Seth M. Steinberg, Jane B. Trepel, William D. Figg, David S. Schrump, Giuseppe Giaccone	79
13	A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent 2014 ·Clinical Cancer Research ·Leonard J. Appleman, Sanjeeve Balasubramaniam, Robert A. Parise, (unknown), Christophe E. Redon, Asako Nakamura, William M. Bonner, James R. Wright, Richard Piekarz, David Köhler, Yixing Jiang, Chandra P. Belani, Julie L. Eiseman, Edward Chu, Jan H. Beumer, Susan E. Bates	5
14	Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers 2013 ·Clinical Cancer Research ·Laleh Amiri‐Kordestani, Victoria Luchenko, Cody J. Peer, Kambiz Ghafourian, James C. Reynolds, (unknown), Robin Frye, (unknown), David Venzon, John J. Wright, Monica C. Skarulis, William D. Figg, Tito Fojo, Susan E. Bates, Richard Piekarz	57
15	Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel 2013 ·Clinical Cancer Research ·Anne M. Noonan, (unknown), David J. Liewehr, Tristan M. Sissung, David Venzon, Thomas P. Flagg, Mark C. Haigney, Seth M. Steinberg, William D. Figg, Richard Piekarz, Susan E. Bates	39
16	A Phase II Trial Of Epigenetic Modulators Vorinostat In Combination With Azacitidine (azaC) In Patients With The Myelodysplastic Syndrome (MDS): Initial Results Of Study 6898 Of The New York Cancer Consortium 2013 ·Blood ·Lewis R. Silverman, Amit Verma, Rosalie Odchimar-Reissig, Eric J. Feldman, Shyamala Navada, Erin P. Demakos, Maria R. Baer, Vesna Najfeld, Joseph A. Sparano, Richard Piekarz	19
17	Romidepsin: A New Drug for the Treatment of Cutaneous T-Cell Lymphoma 2012 ·Clinical journal of oncology nursing ·Robin Frye, (unknown), (unknown), Elizabeth Ness, Richard Piekarz, Susan E. Bates, Susan Booher	45
18	Impact of ABCB1 Allelic Variants on QTc Interval Prolongation 2010 ·Clinical Cancer Research ·Tristan M. Sissung, Erin R. Gardner, Richard Piekarz, Reuben Howden, Xiaohong Chen, Sukyung Woo, Ryan M. Franke, James Clark, Laura Miller‐DeGraff, Seth M. Steinberg, David Venzon, David J. Liewehr, Steven R. Kleeberger, Susan E. Bates, Douglas K. Price, Douglas R. Rosing, Christopher H. Cabell, Alex Sparreboom, William D. Figg	24
19	A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer 2010 ·Clinical Cancer Research ·Ronan J. Kelly, Deborah Draper, Clara C. Chen, Robert W. Robey, William D. Figg, Richard Piekarz, Xiaohong Chen, Erin R. Gardner, Frank M. Balis, Aradhana M. Venkatesan, Seth M. Steinberg, Tito Fojo, Susan E. Bates	151
20	Pharmacokinetic and biomarker analysis in a phase II trial of the HDAC inhibitor romidepsin, FK228 2008 ·Cancer Research ·Richard Piekarz, Erin R. Gardner, Zhirong Zhan, Victoria Luchenko, Seth M. Steinberg, David J. Liewehr, Kenneth Steadman, Robin Frye, William D. Figg, (unknown), Steve Allen, Jasmine Zain, Mark Kirschbaum, Susan E. Bates	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact